The upcoming report from Xeris Biopharma (XERS) is expected to reveal quarterly earnings of $0.03 per share, indicating an increase of 200% compared to the year-ago period. Analysts forecast revenues of $81.43 million, representing an increase of 35.5% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's earnings release, it ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its fourth quarter and full year 2025 financial results before the open of the U.S. financial markets on Monday, March 2, 2026. Management will host a conference call and webcast at 8:30 a.m. Eastern Time that day to di. ...

Core Insights - The article discusses the investment potential of XERS, highlighting a beneficial long position in its shares by the analyst [1]. Group 1 - The analyst expresses a personal opinion on XERS without receiving compensation from the company [1]. - There is an emphasis on the uncertainty of financial predictions and projections, which are merely median estimates [2]. - The article clarifies that past performance does not guarantee future results, and no specific investment advice is provided [3].

Core Viewpoint - Xeris Biopharma Holdings, Inc. has granted restricted stock units to new employees as part of its Inducement Equity Plan, indicating a commitment to attract talent and enhance its workforce [1] Group 1: Company Actions - On January 2, 2026, Xeris granted restricted stock units for a total of 181,550 shares of common stock to 50 new employees [1] - The stock grants are part of Xeris' Inducement Equity Plan, which aims to incentivize and retain key personnel [1]

Core Viewpoint - U.S. stock futures are showing positive movement, particularly with Nasdaq 100 futures increasing by approximately 1% on Friday, while Outlook Therapeutics Inc faces significant stock decline due to FDA's response on its biologics license application [1]. Company Specifics - Outlook Therapeutics Inc (NASDAQ:OTLK) experienced a sharp decline of 60.9%, dropping to $0.62 in pre-market trading after the FDA issued a complete response letter regarding its ONS-5010/LYTENAVA application for treating wet age-related macular degeneration, indicating that the application cannot be approved in its current form [2][1]. - Intelligent Bio Solutions Inc (NASDAQ:INBS) saw a decrease of 19.2%, falling to $7.70 in pre-market trading following the announcement of a $10 million private placement priced at-the-market under Nasdaq rules [3]. - Net Lease Office Properties (NYSE:NLOP) shares dipped by 8.9% to $23.50 in pre-market trading [3]. - Progressive Corp (NYSE:PGR) tumbled by 5.8% to $214.60 in pre-market trading [3]. - Old Republic International Corp (NYSE:ORI) slipped by 4.8% to $43.42 in pre-market trading [3]. - Cango Inc – ADR (NYSE:CANG) fell by 4% to $1.44 in pre-market trading [3]. - Xeris Biopharma Holdings Inc (NASDAQ:XERS) decreased by 3.6% to $7.57 in pre-market trading after a previous gain of over 7% on Wednesday [3]. - Biohaven Ltd (NYSE:BHVN) fell by 2.6% to $11.00 in pre-market trading [3]. - RealReal Inc (NASDAQ:REAL) slipped by 2.3% to $15.41 in pre-market trading [3].

Core Insights - Xeris Biopharma experienced a significant stock price increase of over 7% following the news that a potential commercial threat from Corcept Therapeutics had been neutralized due to the FDA's decision [1][2] - The FDA did not approve Corcept's relacorilant for treating hypertension related to Cushing's syndrome, citing insufficient evidence of the drug's effectiveness [2][3] - Xeris's existing drug, Recorlev, which treats Cushing's syndrome, will not face competition from Corcept's drug, enhancing Xeris's market position [4] Market Analysis - Analyst Glen Santangelo from Jefferies reiterated a buy recommendation for Xeris with a price target of $10, highlighting the growing addressable market for Cushing's disease [5] - The U.S. market for Cushing's syndrome, currently valued at $1 billion, could potentially triple by 2030 if awareness of the disorder increases [6] - Corcept's setback is viewed as a clear advantage for Xeris, positioning the company favorably for future growth [6]

Core Thesis - Xeris Biopharma Holdings, Inc. is transitioning from a survival-stage biotech to a profitable specialty-pharma platform, with a bullish outlook on its growth potential and valuation [1][2]. Financial Performance and Projections - As of December 15th, Xeris' share price was $7.05, with a forward P/E ratio of 64.10 [1]. - Revenue is expected to exceed $360 million by 2026, driven by the growth of Recorlev and the advancement of XP-8121, potentially reaching over $900 million by 2028, with EBITDA margins of 22-25%, generating approximately $240 million in EBITDA [2]. Valuation and Market Position - Xeris trades at a distressed biotech multiple of around 11x forward EBITDA, compared to 12-14x for peers, indicating a potential re-rating opportunity [3]. - A base-case valuation of 12x 2030 EBITDA suggests a share price of $17-18, with a bull case reaching $25-28, while a bear case remains near current levels due to recurring cash flow and a debt-free balance sheet [3]. Growth Model and Strategy - The company's growth model is characterized by a self-reinforcing cash-compounder flywheel, where free cash flow funds debt reduction, lowering risk perception and attracting institutional capital, thus compressing the cost of equity and expanding valuation faster than earnings [4]. - Capital allocation focuses on organic growth, debt retirement, and internal funding for XP-8121, avoiding overextension into unrelated acquisitions [4]. Competitive Advantages - Xeris possesses a multidimensional moat, including proprietary formulation platforms (XeriSol™ and XeriJect™), regulatory exclusivity for Recorlev and XP-8121, and a niche-focused commercial model that enhances pricing power and strategic insulation [5]. - The company targets small, complex markets that are unattractive to Big Pharma, which drives operational precision and profitability [5]. Risk Management - Operational risks include execution, payer adoption, cash-flow timing, and market sentiment, which are mitigated through specialized commercialization, conservative financial management, and consistent delivery [6]. - Xeris' evolution reflects control over cash flow, risk, and perception, positioning it for a compounding re-rating as profitability and growth milestones align [6].

Core Insights - The article identifies 7 hidden multibagger stocks that have shown significant returns and potential upside, emphasizing the importance of selecting stocks with strong fundamentals and growth prospects [1][5]. Group 1: Stock Selection Criteria - Stocks were selected based on a minimum return of 75% over the past year and a market capitalization of at least $1 billion [1]. - The shortlisted stocks were required to have at least 30% potential upside, leading to a ranking of the top 7 stocks [1]. Group 2: Market Outlook - The S&P 500 index is expected to show positive performance for the third consecutive year, with AI adoption potentially driving a productivity boom similar to the late 90s [3]. - Goldman Sachs anticipates that reducing tariff uncertainties could enhance economic security, leading to increased capital deployment in defense, energy, and infrastructure sectors [4]. Group 3: Individual Stock Highlights - **Praxis Precision Medicines, Inc. (NASDAQ:PRAX)**: Achieved a 264% price return over the past year with a potential upside of 33%. The company reported positive results from a key study on a treatment for severe epilepsy [6][8]. - **Solaris Resources Inc. (NYSEAMERICAN:SLSR)**: Recorded a 139% price return with a potential upside of 43.36%. The company is focused on copper and other minerals, with a significant project expected to produce 4.5 million tonnes of Copper Equivalent [10][11]. - **Ouster Inc. (NASDAQ:OUST)**: Experienced a 138.5% price return and has a potential upside of 55.37%. The company is noted for its strong client base and growth prospects in lidar sensor technology [14][15]. - **Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)**: Achieved a 75% price return with a potential upside of 61.3%. The company is advancing a new formulation for hypothyroidism treatment [18][19]. - **Applied Digital Corporation (NASDAQ:APLD)**: Saw a 192.6% price return and has a potential upside of 62.36%. The company is investing in advanced cooling systems for data centers, positioning itself for growth in the AI sector [21][22]. - **IREN Limited (NASDAQ:IREN)**: Recorded a 190.5% price return with a potential upside of 91.23%. Despite recent funding challenges, the company has strong fundamentals supported by a significant AI contract with Microsoft [24][26]. - **UniQURE (NASDAQ:QURE)**: Achieved a 186% price return with a potential upside of 117.16%. The company is developing a gene therapy for Huntington's disease, although it faces regulatory challenges [28][29].

Summary of Xeris Biopharma Holdings FY Conference Call Company Overview - **Company**: Xeris Biopharma Holdings (NasdaqGS:XERS) - **Industry**: Biopharmaceuticals - **Products**: Gvoke HypoPen, Keveyus, Recorlev - **Growth**: The company has raised its revenue guidance to $285 million-$290 million, reflecting a 42% growth at the midpoint [2][3] Core Insights Financial Performance - **Gross Margins**: The company reports 85% gross margins, which are improving [2] - **EBITDA**: Adjusted EBITDA became positive a year ago, with net income reported for the first time last quarter [3] Product Focus: Recorlev - **Market Awareness**: Increased screening for hypercortisolism among endocrinologists is driving Recorlev's growth, particularly in patients with uncontrolled type 2 diabetes and hypertension [4][5] - **Patient Demographics**: Patients treated with Recorlev have hypercortisolemia, with cortisol levels 1.8 times or higher than normal, often accompanied by conditions like diabetes or obesity [6] - **Sales Force Expansion**: The sales force was increased by 50% in August 2024 and is set to double by January 2026, targeting 12,000 physicians [10][11] - **Payer Access**: The focus is on demonstrating medical necessity for patients with hypercortisolemia to facilitate access [16] - **Competitive Landscape**: The entry of Corcept's relacorilant is seen as beneficial for overall market awareness, with no expected disruption to Recorlev's sales [18][20] Product Focus: Gvoke - **Market Penetration**: Gvoke is primarily used in type 1 diabetes, with efforts ongoing to increase awareness among clinicians regarding its necessity for patients on insulin or sulfonylurea [26][30] - **Payer Access**: Over 80% access is reported, with the main challenge being clinician awareness rather than payer issues [33] - **Competitive Dynamics**: The market can accommodate both Gvoke and Baqsimi without significant competitive disruption [36] Product Focus: Keveyus - **Market Position**: Despite generic competition, Keveyus maintains steady sales around $11 million per quarter due to comprehensive patient support services [41] Pipeline Product: XP-8121 - **Market Opportunity**: Targeting 3-5 million patients who cannot achieve normal thyroid levels due to GI absorption issues, with a projected market opportunity of $1 billion-$3 billion [43][49] - **Phase 3 Trial**: A phase 3 trial is planned for late 2026, aiming to establish therapeutic equivalence to daily oral levothyroxine [50] Additional Insights - **Intellectual Property**: Xeris holds multiple patents for Recorlev, with protections extending to 2040, which strengthens its market position against generics [22][23] - **Acquisition Strategy**: The company is open to acquiring assets that can leverage its existing commercial infrastructure, targeting $750 million in revenue by 2030 [54] Conclusion Xeris Biopharma is positioned for significant growth driven by its key products, particularly Recorlev, with a strong focus on expanding its market presence and enhancing patient access. The company is also strategically planning for future product launches and potential acquisitions to bolster its portfolio.

Revenue Growth - For the three months ended September 30, 2025, net product revenue increased by $21.2 million or 40.1% to $74.1 million compared to $52.9 million for the same period in 2024[134]. - Recorlev's net revenue rose by $19.2 million or 108.6% for the three months ended September 30, 2025, primarily due to increased patient demand, despite a $1.4 million unfavorable net pricing impact[135]. - Gvoke's net revenue increased by $2.2 million or 9.6% for the three months ended September 30, 2025, reaching $25.2 million compared to $22.9 million in the same period of 2024[134]. - Total revenue for the nine months ended September 30, 2025, was $206.0 million, an increase of $63.1 million or 44.1% compared to $143.0 million for the same period in 2024[134]. - Net revenue increased by $52.3 million or 125.5% for the nine months ended September 30, 2025, primarily driven by higher volume of $56.3 million or 135.1%[136]. - Gvoke's net revenue increased by $2.2 million or 9.6% for the three months ended September 30, 2025, due to higher volume of $0.6 million or 2.7% and favorable net pricing of $1.6 million or 6.9%[137]. - Keveyis' net revenue decreased by $0.3 million or 2.1% for the three months ended September 30, 2025, due to unfavorable net pricing of $1.1 million or 8.8%[139]. Expenses - Research and development expenses for the three months ended September 30, 2025, were $7.5 million, an increase of $1.6 million or 27.1% compared to $5.9 million in the same period of 2024[134]. - Selling, general and administrative expenses for the three months ended September 30, 2025, were $46.5 million, an increase of $1.5 million or 3.3% compared to $45.0 million in the same period of 2024[134]. - Research and development expenses increased by $3.8 million or 19.6% for the nine months ended September 30, 2025, with project-specific expenses for pipeline increasing by $1.4 million or 25.6%[145]. - Selling, general and administrative expenses increased by $11.5 million or 9.3% for the nine months ended September 30, 2025, primarily due to higher personnel-related expenses of $7.9 million[147]. Net Loss and Financial Position - The company reported a net loss of $15.7 million for the nine months ended September 30, 2025, compared to a net loss of $49.7 million for the same period in 2024, reflecting a decrease of $34.0 million or 68.4%[134]. - The accumulated deficit as of September 30, 2025, was $682.4 million, indicating ongoing financial challenges despite revenue growth[121]. - The company has an accumulated deficit of $682.4 million as of September 30, 2025, and expects to incur substantial additional expenditures in the near term[157]. Cash Flow - Net cash provided by operating activities was $8.6 million for the nine months ended September 30, 2025, compared to $39.0 million used in operating activities for the same period in 2024[161]. - Net cash provided by financing activities was $11.7 million for the nine months ended September 30, 2025, driven by proceeds from the exercise of stock awards and issuance of common shares[163]. Patents and Clinical Trials - As of October 31, 2025, the company owned 191 patents globally, including key patents for its glucagon formulation expiring in 2036[120]. - The company plans to initiate a Phase 3 clinical trial for XP-8121, a once-weekly subcutaneous injection of levothyroxine for hypothyroidism[118]. Cost of Goods Sold - Cost of goods sold as a percent of total product revenue improved by 3.8%, to 15.8% for the nine months ended September 30, 2025, primarily due to higher sales of products with a lower cost of goods sold[144]. Foreign Currency Risk - The company is exposed to foreign currency exchange risk due to contracts with organizations outside the United States[169]. - Net foreign currency gains and losses did not have a material effect on the company's results of operations for the three and nine months ended September 30, 2025[169]. Interest Expense - Interest expense decreased by $0.9 million or 3.7% for the nine months ended September 30, 2025, primarily due to a lower principal amount of debt outstanding[150].